erlotinib hydrochloride has been researched along with apatinib in 2 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (apatinib) | Trials (apatinib) | Recent Studies (post-2010) (apatinib) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 575 | 109 | 544 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | apatinib (IC50) |
|---|---|---|---|
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.001 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jin, T; Li, C; Tian, SM; Wu, JJ; Wu, YP; Xie, K | 1 |
| Chen, J; Li, X; Liu, H; Liu, M; Zhang, H | 1 |
1 trial(s) available for erlotinib hydrochloride and apatinib
| Article | Year |
|---|---|
Clinical study of apatinib combined with EGFR-TKI in the treatment of chronic progression after EGFR-TKI treatment in non-small cell lung cancer (ChiCTR1800019185).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Prospective Studies; Pyridines; Quinazolines; Research Design; Young Adult | 2020 |
1 other study(ies) available for erlotinib hydrochloride and apatinib
| Article | Year |
|---|---|
Apatinib with EGFR-TKIs in advanced wild gene-type NSCLC: A case report.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Karnofsky Performance Status; Protein Kinase Inhibitors; Pyridines; Treatment Outcome | 2019 |